These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

309 related items for PubMed ID: 9818279

  • 21. Somatostatin receptor scintigraphy with 111In-pentetreotide in non-functioning gastroenteropancreatic neuroendocrine tumors.
    Schillaci O, Spanu A, Scopinaro F, Falchi A, Corleto V, Danieli R, Marongiu P, Pisu N, Madeddu G, Delle Fave G, Madeddu G.
    Int J Oncol; 2003 Dec; 23(6):1687-95. PubMed ID: 14612942
    [Abstract] [Full Text] [Related]

  • 22. Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours.
    Ambrosini V, Tomassetti P, Castellucci P, Campana D, Montini G, Rubello D, Nanni C, Rizzello A, Franchi R, Fanti S.
    Eur J Nucl Med Mol Imaging; 2008 Aug; 35(8):1431-8. PubMed ID: 18418596
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. 111In-pentetreotide (somatostatin analogue) scintigraphy as an imaging procedure for endocrine gastro-entero-pancreatic tumors.
    Nauck C, Ivancević V, Emrich D, Creutzfeldt W.
    Z Gastroenterol; 1994 Jun; 32(6):323-7. PubMed ID: 7975760
    [Abstract] [Full Text] [Related]

  • 27. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours.
    Adams S, Baum R, Rink T, Schumm-Dräger PM, Usadel KH, Hör G.
    Eur J Nucl Med; 1998 Jan; 25(1):79-83. PubMed ID: 9396878
    [Abstract] [Full Text] [Related]

  • 28. Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours.
    Teunissen JJ, Kwekkeboom DJ, Valkema R, Krenning EP.
    Endocr Relat Cancer; 2011 Oct; 18 Suppl 1():S27-51. PubMed ID: 22005114
    [Abstract] [Full Text] [Related]

  • 29. Somatostatin-receptor imaging of neuroendocrine gastroenteropancreatic tumors.
    Scherübl H, Bäder M, Fett U, Hamm B, Schmidt-Gayk H, Koppenhagen K, Dop FJ, Riecken EO, Wiedenmann B.
    Gastroenterology; 1993 Dec; 105(6):1705-9. PubMed ID: 7902821
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. High management impact of Ga-68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours.
    Hofman MS, Kong G, Neels OC, Eu P, Hong E, Hicks RJ.
    J Med Imaging Radiat Oncol; 2012 Feb; 56(1):40-7. PubMed ID: 22339744
    [Abstract] [Full Text] [Related]

  • 32. SPECT/CT hybrid imaging with 111In-pentetreotide in assessment of neuroendocrine tumours.
    Krausz Y, Keidar Z, Kogan I, Even-Sapir E, Bar-Shalom R, Engel A, Rubinstein R, Sachs J, Bocher M, Agranovicz S, Chisin R, Israel O.
    Clin Endocrinol (Oxf); 2003 Nov; 59(5):565-73. PubMed ID: 14616879
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. The clinical impact of a combined gamma camera/CT imaging system on somatostatin receptor imaging of neuroendocrine tumours.
    Hillel PG, van Beek EJ, Taylor C, Lorenz E, Bax ND, Prakash V, Tindale WB.
    Clin Radiol; 2006 Jul; 61(7):579-87. PubMed ID: 16784943
    [Abstract] [Full Text] [Related]

  • 35. Imaging of neuroendocrine tumors: accuracy of helical CT versus SRS.
    Kumbasar B, Kamel IR, Tekes A, Eng J, Fishman EK, Wahl RL.
    Abdom Imaging; 2004 Jul; 29(6):696-702. PubMed ID: 15162235
    [Abstract] [Full Text] [Related]

  • 36. Current knowledge on the sensitivity of the (68)Ga-somatostatin receptor positron emission tomography and the SUVmax reference range for management of pancreatic neuroendocrine tumours.
    Virgolini I, Gabriel M, Kroiss A, von Guggenberg E, Prommegger R, Warwitz B, Nilica B, Roig LG, Rodrigues M, Uprimny C.
    Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):2072-83. PubMed ID: 27174220
    [Abstract] [Full Text] [Related]

  • 37. Metabolic and receptor imaging in patients with neuroendocrine tumors: comparison of fludeoxyglucose-positron emission tomography and computed tomography with indium in 111 pentetreotide.
    Zalom ML, Waxman AD, Yu R, Lee J, Ih G, Wolin EM.
    Endocr Pract; 2009 Oct; 15(6):521-7. PubMed ID: 19491080
    [Abstract] [Full Text] [Related]

  • 38. Clinical Usefulness of Somatostatin Receptor Scintigraphy in Japanese Patients with Gastroenteropancreatic Neuroendocrine Tumors.
    Hasegawa S, Kobayashi N, Tokuhisa M, Goto A, Takano S, Takada Y, Kaneta T, Mori R, Matsuyama R, Endo I, Yamanaka S, Nakajima A, Inoue T, Ichikawa Y.
    Digestion; 2017 Oct; 96(1):13-20. PubMed ID: 28609761
    [Abstract] [Full Text] [Related]

  • 39. Incremental diagnostic value and impact on patient management of somatostatin receptor scintigraphy with indium-111-pentetreotide in gastroenteropancreatic neuroendocrine tumors.
    Usmani S, Khan HA, Abdulla M, Ahmed N, abu Huda F, Marafi F, al Kandari F, al Mohannadi S, al Nafisi N.
    Med Princ Pract; 2011 Oct; 20(4):356-61. PubMed ID: 21576997
    [Abstract] [Full Text] [Related]

  • 40. The multidisciplinary team for gastroenteropancreatic neuroendocrine tumours: the radiologist's challenge.
    Granata V, Fusco R, Setola SV, Castelguidone ELD, Camera L, Tafuto S, Avallone A, Belli A, Incollingo P, Palaia R, Izzo F, Petrillo A.
    Radiol Oncol; 2019 Oct 25; 53(4):373-387. PubMed ID: 31652122
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.